Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.11 CAD | -0.49% | +2.86% | +17.73% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 1,028 | 695.7 | 629.6 | 583.6 | 540.7 | 619.4 | - | - |
Enterprise Value (EV) 1 | 1,028 | 695.7 | 629.6 | 583.6 | 540.7 | 619.4 | 619.4 | 619.4 |
P/E ratio | 75.8 x | 16.8 x | 40.8 x | -19.9 x | -32.4 x | 214 x | 59.9 x | 49.5 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 21.7 x | 3.49 x | 2.59 x | 1.99 x | 1.65 x | 1.79 x | 1.74 x | 1.62 x |
EV / Revenue | 21.7 x | 3.49 x | 2.59 x | 1.99 x | 1.65 x | 1.79 x | 1.74 x | 1.62 x |
EV / EBITDA | -111 x | 41.3 x | 16.6 x | 10.8 x | 9 x | 10.6 x | 9.77 x | 8.26 x |
EV / FCF | 229 x | -39.6 x | 15.4 x | 15.5 x | - | 21.4 x | 20.1 x | 16 x |
FCF Yield | 0.44% | -2.53% | 6.48% | 6.44% | - | 4.67% | 4.97% | 6.26% |
Price to Book | 1.27 x | 0.79 x | 0.74 x | 0.7 x | - | 0.84 x | 0.81 x | 0.84 x |
Nbr of stocks (in thousands) | 135,629 | 130,035 | 118,786 | 112,672 | 104,187 | 101,376 | - | - |
Reference price 2 | 7.580 | 5.350 | 5.300 | 5.180 | 5.190 | 6.110 | 6.110 | 6.110 |
Announcement Date | 3/30/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 47.46 | 199.5 | 243.5 | 293.6 | 328.2 | 345.9 | 356.3 | 381.4 |
EBITDA 1 | -9.244 | 16.84 | 38 | 54.03 | 60.08 | 58.22 | 63.38 | 74.95 |
EBIT 1 | - | -4.465 | 28.34 | 34.68 | 51.41 | 54.18 | - | - |
Operating Margin | - | -2.24% | 11.64% | 11.81% | 15.66% | 15.66% | - | - |
Earnings before Tax (EBT) 1 | 22.78 | 32.08 | 6.69 | -43.96 | -21.99 | -3.517 | 11.5 | 26.44 |
Net income 1 | 14.52 | 42.07 | 15.68 | -29.89 | -16.84 | 2.488 | 13.69 | 13.8 |
Net margin | 30.59% | 21.08% | 6.44% | -10.18% | -5.13% | 0.72% | 3.84% | 3.62% |
EPS 2 | 0.1000 | 0.3190 | 0.1300 | -0.2600 | -0.1600 | 0.0286 | 0.1020 | 0.1233 |
Free Cash Flow 1 | 4.487 | -17.58 | 40.79 | 37.6 | - | 28.9 | 30.8 | 38.8 |
FCF margin | 9.45% | -8.81% | 16.75% | 12.81% | - | 8.36% | 8.64% | 10.17% |
FCF Conversion (EBITDA) | - | - | 107.32% | 69.58% | - | 49.64% | 48.6% | 51.77% |
FCF Conversion (Net income) | 30.91% | - | 260.2% | - | - | 1,161.34% | 225.05% | 281.16% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/30/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 58.27 | 63.81 | 75.82 | 72.28 | 81.66 | 82.6 | 89.9 | 81.5 | 74.2 | 86.6 | 87.67 | 86.72 | 84.94 | 87.3 | 90.5 |
EBITDA 1 | 5.696 | 13.31 | 17.89 | 9.009 | 13.82 | 18.24 | 14.27 | 15.51 | 12.06 | 13.59 | 14.69 | 15.12 | 14.31 | 15.05 | 15.6 |
EBIT 1 | 2.406 | 10.97 | 13.39 | 2.309 | 8.01 | 16.8 | 11.16 | 12.41 | 11.03 | 13.53 | 10.76 | 14.7 | 15.19 | - | - |
Operating Margin | 4.13% | 17.2% | 17.66% | 3.19% | 9.81% | 20.34% | 12.42% | 15.23% | 14.87% | 15.63% | 12.28% | 16.95% | 17.88% | - | - |
Earnings before Tax (EBT) 1 | -14.42 | -22.31 | 0.636 | 0.851 | -23.14 | -4.946 | 0.212 | 8.898 | -26.15 | -7.144 | 0.6508 | 1.346 | 1.834 | 1 | 1.8 |
Net income 1 | -8.301 | -18.81 | 2.516 | 1.591 | -15.19 | -3.937 | 1.84 | 9.588 | -24.33 | -4.546 | 0.7197 | 1.411 | 1.463 | 0.8 | 1.4 |
Net margin | -14.25% | -29.48% | 3.32% | 2.2% | -18.6% | -4.77% | 2.05% | 11.76% | -32.79% | -5.25% | 0.82% | 1.63% | 1.72% | 0.92% | 1.55% |
EPS 2 | -0.0600 | -0.1600 | 0.0200 | 0.0100 | -0.1300 | -0.0400 | 0.0200 | 0.0900 | -0.2300 | -0.0400 | 0.0160 | 0.0240 | 0.0260 | 0.0100 | 0.0100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/24/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/21/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | 4.49 | -17.6 | 40.8 | 37.6 | - | 28.9 | 30.8 | 38.8 |
ROE (net income / shareholders' equity) | 1.58% | 4.96% | - | -3.58% | - | -0.5% | 2% | 3.6% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 5.990 | 6.820 | 7.150 | 7.360 | - | 7.290 | 7.500 | 7.250 |
Cash Flow per Share 2 | 0.0300 | - | - | 0.3500 | - | 0.1000 | 0.4600 | 0.4100 |
Capex 1 | 0.11 | 5.38 | 224 | 2.89 | - | 7.93 | 10 | 10 |
Capex / Sales | 0.23% | 2.7% | 92.08% | 0.98% | - | 2.29% | 2.81% | 2.62% |
Announcement Date | 3/30/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.73% | 455M | |
+10.23% | 8.96B | |
-10.76% | 5.19B | |
+51.58% | 4.77B | |
+12.50% | 4.26B | |
-20.70% | 2.37B | |
+12.83% | 2.3B | |
+19.51% | 2.17B | |
-29.65% | 2.21B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- GUD Stock
- Financials Knight Therapeutics Inc.